{
    "xml": "<topic id=\"PHP904\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/dronedarone\" basename=\"dronedarone\" title=\"DRONEDARONE\">\n<title>DRONEDARONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1176\" namespace=\"/interactions/list-of-drug-interactions/anti-arrhythmics/dronedarone\">Dronedarone</xref>\n</p>\n<data name=\"vtmid\">443310000</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_252514551\" title=\"Antiarrhythmics\">Antiarrhythmics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP38615\" outputclass=\"drugAction\" rev=\"1.9\" parent=\"/drugs/dronedarone\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dronedarone is a multi-channel blocking anti-arrhythmic drug.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38605\" outputclass=\"indicationsAndDose\" rev=\"1.10\" parent=\"/drugs/dronedarone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance of sinus rhythm after cardioversion in clinically stable patients with paroxysmal or persistent atrial fibrillation, when alternative treatments are unsuitable (initiated under specialist supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>400&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38623\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/dronedarone\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Atrial conduction defects</ph>; <ph outputclass=\"contraindication\">bradycardia</ph>; <ph outputclass=\"contraindication\">complete bundle branch block</ph>; <ph outputclass=\"contraindication\">distal block</ph>; <ph outputclass=\"contraindication\">existing or previous heart failure or left ventricular systolic dysfunction</ph>; <ph outputclass=\"contraindication\">haemodynamically unstable patients</ph>; <ph outputclass=\"contraindication\">liver toxicity associated with previous amiodarone use</ph>; <ph outputclass=\"contraindication\">lung toxicity associated with previous amiodarone use</ph>; <ph outputclass=\"contraindication\">permanent atrial fibrillation</ph>; <ph outputclass=\"contraindication\">prolonged QT interval</ph>; <ph outputclass=\"contraindication\">second- or third- degree AV block</ph>; <ph outputclass=\"contraindication\">sick sinus syndrome (unless pacemaker fitted)</ph>; <ph outputclass=\"contraindication\">sinus node dysfunction</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38630\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/dronedarone\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Coronary artery disease</ph>; <ph outputclass=\"caution\">correct hypokalaemia and hypomagnesaemia before starting and during treatment</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38602\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/dronedarone\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (dronedarone).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38578\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/dronedarone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bradycardia</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">heart failure</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">QT-interval prolongation</ph>; <ph outputclass=\"sideEffect\">raised serum creatinine</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dermatitis</ph>; <ph outputclass=\"sideEffect\">eczema</ph>; <ph outputclass=\"sideEffect\">erythema</ph>; <ph outputclass=\"sideEffect\">interstitial lung disease (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)</ph>; <ph outputclass=\"sideEffect\">photosensitivity</ph>; <ph outputclass=\"sideEffect\">pneumonitis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)</ph>; <ph outputclass=\"sideEffect\">pulmonary fibrosis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Liver injury (including life-threatening acute liver failure)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Liver injury</p>\n<p>Liver injury, including life-threatening acute liver failure reported rarely; discontinue treatment if 2 consecutive alanine aminotransferase concentrations exceed 3 times upper limit of normal.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Heart failure</p>\n<p>New onset or worsening heart failure reported. If heart failure or left ventricular systolic dysfunction develops, discontinue treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38597\" outputclass=\"pregnancy\" parent=\"/drugs/dronedarone\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38632\" outputclass=\"breastFeeding\" parent=\"/drugs/dronedarone\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38609\" outputclass=\"hepaticImpairment\" parent=\"/drugs/dronedarone\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38587\" outputclass=\"renalImpairment\" parent=\"/drugs/dronedarone\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38564\" outputclass=\"monitoringRequirements\" parent=\"/drugs/dronedarone\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Ongoing monitoring should occur under specialist supervision.</p>\n<p>Monitor for heart failure.</p>\n<p>Perform ECG at least every 6 months&#8212;consider discontinuation if atrial fibrillation reoccurs.</p>\n<p>Measure serum creatinine before treatment and 7 days after initiation&#8212;if raised, measure again after a further 7 days and consider discontinuation if creatinine continues to rise.</p>\n<p>Monitor liver function before treatment, 1 week and 1 month after initiation of treatment, then monthly for 6 months, then every 3 months for 6 months and periodically thereafter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38593\" outputclass=\"patientAndCarerAdvice\" rev=\"1.8\" parent=\"/drugs/dronedarone\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Heart failure</p>\n<p>Patients or their carers should be told how to recognise signs of heart failure and advised to seek prompt medical attention if symptoms such as weight gain, dependent oedema, or dyspnoea develop or worsen.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hepatic disorders</p>\n<p>Patients or their carers should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as abdominal pain, anorexia, nausea, vomiting, fever, malaise, itching, dark urine, or jaundice develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38552\" outputclass=\"nationalFunding\" rev=\"1.21\" parent=\"/drugs/dronedarone\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA197</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dronedarone for the treatment of non-permanent atrial fibrillation (December 2012)</p>\r\n<p>Dronedarone is an option for the maintenance of sinus rhythm after successful cardioversion in paroxysmal or persistent atrial fibrillation which is not controlled by first-line therapy (usually including beta-blockers), <b>and</b> after alternative options have been considered in patients:</p>\r\n<ul>\r\n<li>who have at least 1 of the following cardiovascular risk factors: hypertension requiring drugs of at least 2 different classes, diabetes mellitus, previous transient ischaemic attack, stroke or systemic embolism, left atrial diameter of 50&#8239;mm or greater, or age 70 years or older <b>and</b>\r\n</li>\r\n<li>who do not have left ventricular systolic dysfunction nor a history of, or current, heart failure</li>\r\n</ul>\r\n<p>Patients who do not meet the above criteria who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA197\">www.nice.org.uk/TA197</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP904-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/dronedarone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75065\" title=\"Tablet\" namespace=\"/drugs/dronedarone/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78291\" namespace=\"/treatment-summaries/arrhythmias\" title=\"Arrhythmias\" count=\"2\" rel=\"backlink\">Arrhythmias</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1176\" namespace=\"/interactions/list-of-drug-interactions/anti-arrhythmics/dronedarone\" title=\"Dronedarone\" count=\"1\" rel=\"link\">Dronedarone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75065\" namespace=\"/drugs/dronedarone/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP904",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/dronedarone",
    "basename": "dronedarone",
    "title": "DRONEDARONE",
    "interactants": [
        {
            "id": "bnf_int_1176",
            "label": "Dronedarone"
        }
    ],
    "vtmid": "443310000",
    "drugClassification": [
        "Antiarrhythmics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Dronedarone is a multi-channel blocking anti-arrhythmic drug.",
                "html": "<p>Dronedarone is a multi-channel blocking anti-arrhythmic drug.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Maintenance of sinus rhythm after cardioversion in clinically stable patients with paroxysmal or persistent atrial fibrillation, when alternative treatments are unsuitable (initiated under specialist supervision)",
                        "html": "Maintenance of sinus rhythm after cardioversion in clinically stable patients with paroxysmal or persistent atrial fibrillation, when alternative treatments are unsuitable (initiated under specialist supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "400 mg twice daily.",
                        "html": "<p>400&#8239;mg twice daily.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Atrial conduction defects",
                "html": "Atrial conduction defects"
            },
            {
                "type": "contraindications",
                "textContent": "bradycardia",
                "html": "bradycardia"
            },
            {
                "type": "contraindications",
                "textContent": "complete bundle branch block",
                "html": "complete bundle branch block"
            },
            {
                "type": "contraindications",
                "textContent": "distal block",
                "html": "distal block"
            },
            {
                "type": "contraindications",
                "textContent": "existing or previous heart failure or left ventricular systolic dysfunction",
                "html": "existing or previous heart failure or left ventricular systolic dysfunction"
            },
            {
                "type": "contraindications",
                "textContent": "haemodynamically unstable patients",
                "html": "haemodynamically unstable patients"
            },
            {
                "type": "contraindications",
                "textContent": "liver toxicity associated with previous amiodarone use",
                "html": "liver toxicity associated with previous amiodarone use"
            },
            {
                "type": "contraindications",
                "textContent": "lung toxicity associated with previous amiodarone use",
                "html": "lung toxicity associated with previous amiodarone use"
            },
            {
                "type": "contraindications",
                "textContent": "permanent atrial fibrillation",
                "html": "permanent atrial fibrillation"
            },
            {
                "type": "contraindications",
                "textContent": "prolonged QT interval",
                "html": "prolonged QT interval"
            },
            {
                "type": "contraindications",
                "textContent": "second- or third- degree AV block",
                "html": "second- or third- degree AV block"
            },
            {
                "type": "contraindications",
                "textContent": "sick sinus syndrome (unless pacemaker fitted)",
                "html": "sick sinus syndrome (unless pacemaker fitted)"
            },
            {
                "type": "contraindications",
                "textContent": "sinus node dysfunction",
                "html": "sinus node dysfunction"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Coronary artery disease",
                "html": "Coronary artery disease"
            },
            {
                "type": "cautions",
                "textContent": "correct hypokalaemia and hypomagnesaemia before starting and during treatment",
                "html": "correct hypokalaemia and hypomagnesaemia before starting and during treatment"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (dronedarone).",
                "html": "<p>Appendix 1 (dronedarone).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Bradycardia",
                        "html": "Bradycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "heart failure",
                        "html": "heart failure",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "QT-interval prolongation",
                        "html": "QT-interval prolongation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised serum creatinine",
                        "html": "raised serum creatinine",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dermatitis",
                        "html": "Dermatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "eczema",
                        "html": "eczema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "erythema",
                        "html": "erythema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "interstitial lung disease (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)",
                        "html": "interstitial lung disease (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "photosensitivity",
                        "html": "photosensitivity",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pneumonitis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)",
                        "html": "pneumonitis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pulmonary fibrosis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)",
                        "html": "pulmonary fibrosis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Liver injury (including life-threatening acute liver failure)",
                        "html": "Liver injury (including life-threatening acute liver failure)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Liver injury",
                "textContent": "Liver injury, including life-threatening acute liver failure reported rarely; discontinue treatment if 2 consecutive alanine aminotransferase concentrations exceed 3 times upper limit of normal.",
                "html": "<p>Liver injury, including life-threatening acute liver failure reported rarely; discontinue treatment if 2 consecutive alanine aminotransferase concentrations exceed 3 times upper limit of normal.</p>"
            },
            {
                "type": "advice",
                "title": "Heart failure",
                "textContent": "New onset or worsening heart failure reported. If heart failure or left ventricular systolic dysfunction develops, discontinue treatment.",
                "html": "<p>New onset or worsening heart failure reported. If heart failure or left ventricular systolic dysfunction develops, discontinue treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Ongoing monitoring should occur under specialist supervision.\n\nMonitor for heart failure.\n\nPerform ECG at least every 6 months&#8212;consider discontinuation if atrial fibrillation reoccurs.\n\nMeasure serum creatinine before treatment and 7 days after initiation&#8212;if raised, measure again after a further 7 days and consider discontinuation if creatinine continues to rise.\n\nMonitor liver function before treatment, 1 week and 1 month after initiation of treatment, then monthly for 6 months, then every 3 months for 6 months and periodically thereafter.",
                "html": "<p>Ongoing monitoring should occur under specialist supervision.</p><p>Monitor for heart failure.</p><p>Perform ECG at least every 6 months&#8212;consider discontinuation if atrial fibrillation reoccurs.</p><p>Measure serum creatinine before treatment and 7 days after initiation&#8212;if raised, measure again after a further 7 days and consider discontinuation if creatinine continues to rise.</p><p>Monitor liver function before treatment, 1 week and 1 month after initiation of treatment, then monthly for 6 months, then every 3 months for 6 months and periodically thereafter.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Heart failure",
                "textContent": "Patients or their carers should be told how to recognise signs of heart failure and advised to seek prompt medical attention if symptoms such as weight gain, dependent oedema, or dyspnoea develop or worsen.",
                "html": "<p>Patients or their carers should be told how to recognise signs of heart failure and advised to seek prompt medical attention if symptoms such as weight gain, dependent oedema, or dyspnoea develop or worsen.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Hepatic disorders",
                "textContent": "Patients or their carers should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as abdominal pain, anorexia, nausea, vomiting, fever, malaise, itching, dark urine, or jaundice develop.",
                "html": "<p>Patients or their carers should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as abdominal pain, anorexia, nausea, vomiting, fever, malaise, itching, dark urine, or jaundice develop.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA197",
                        "label": "www.nice.org.uk/TA197"
                    }
                ],
                "fundingIdentifier": "NICE TA197",
                "textContent": "Dronedarone for the treatment of non-permanent atrial fibrillation (December 2012) Dronedarone is an option for the maintenance of sinus rhythm after successful cardioversion in paroxysmal or persistent atrial fibrillation which is not controlled by first-line therapy (usually including beta-blockers), and after alternative options have been considered in patients: who have at least 1 of the following cardiovascular risk factors: hypertension requiring drugs of at least 2 different classes, diabetes mellitus, previous transient ischaemic attack, stroke or systemic embolism, left atrial diameter of 50 mm or greater, or age 70 years or older and who do not have left ventricular systolic dysfunction nor a history of, or current, heart failure Patients who do not meet the above criteria who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.\n\nwww.nice.org.uk/TA197",
                "html": "<p outputclass=\"title\">Dronedarone for the treatment of non-permanent atrial fibrillation (December 2012)</p> <p>Dronedarone is an option for the maintenance of sinus rhythm after successful cardioversion in paroxysmal or persistent atrial fibrillation which is not controlled by first-line therapy (usually including beta-blockers), <b>and</b> after alternative options have been considered in patients:</p> <ul> <li>who have at least 1 of the following cardiovascular risk factors: hypertension requiring drugs of at least 2 different classes, diabetes mellitus, previous transient ischaemic attack, stroke or systemic embolism, left atrial diameter of 50&#8239;mm or greater, or age 70 years or older <b>and</b> </li> <li>who do not have left ventricular systolic dysfunction nor a history of, or current, heart failure</li> </ul> <p>Patients who do not meet the above criteria who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA197\">www.nice.org.uk/TA197</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75065",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78291",
                "label": "Arrhythmias",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1176",
                "label": "Dronedarone",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75065",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}